Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

2.

Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

Symmons DP, Silman AJ.

Arthritis Rheum. 2004 Jun;50(6):1703-6. Review. No abstract available.

3.

Rheumatoid arthritis and malignant lymphomas.

Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L.

Curr Opin Rheumatol. 2004 May;16(3):254-61. Review.

PMID:
15103253
4.

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.

Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL.

Ann Rheum Dis. 2003 Aug;62(8):722-7.

5.

Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.

Baecklund E, Sundström C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, Klareskog L.

Arthritis Rheum. 2003 Jun;48(6):1543-50.

6.

The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.

Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF; West Midlands Rheumatology Services and Training Committee.

Rheumatology (Oxford). 2003 Jul;42(7):856-9. Epub 2003 Mar 31.

PMID:
12730544
7.

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM.

Arthritis Rheum. 2002 Dec;46(12):3151-8.

8.

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Geborek P, Crnkic M, Petersson IF, Saxne T; South Swedish Arthritis Treatment Group.

Ann Rheum Dis. 2002 Sep;61(9):793-8.

9.

Cancer risk in patients with inflammatory bowel disease: a population-based study.

Bernstein CN, Blanchard JF, Kliewer E, Wajda A.

Cancer. 2001 Feb 15;91(4):854-62.

PMID:
11241255
10.

Risk of malignancy among patients with rheumatic conditions.

Thomas E, Brewster DH, Black RJ, Macfarlane GJ.

Int J Cancer. 2000 Nov 1;88(3):497-502.

11.

Extra-articular rheumatoid arthritis: prevalence and mortality.

Turesson C, Jacobsson L, Bergström U.

Rheumatology (Oxford). 1999 Jul;38(7):668-74.

PMID:
10461483
12.

A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis.

Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A.

J Rheumatol. 1999 Aug;26(8):1676-80.

PMID:
10451061
13.

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L.

BMJ. 1998 Jul 18;317(7152):180-1. No abstract available.

14.

Rheumatoid arthritis and the risk of malignancy.

Cibere J, Sibley J, Haga M.

Arthritis Rheum. 1997 Sep;40(9):1580-6.

PMID:
9324011
15.

Cigarette smoking and rheumatoid arthritis severity.

Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA.

Ann Rheum Dis. 1997 Aug;56(8):463-9.

16.

Is methotrexate oncogenic in patients with rheumatoid arthritis?

Kremer JM.

Semin Arthritis Rheum. 1997 Jun;26(6):785-7. No abstract available.

PMID:
9213376
17.

Rheumatoid arthritis and cancer risk.

Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH.

Eur J Cancer. 1996 Sep;32A(10):1753-7.

PMID:
8983286
19.

Excess risk of lung cancer in patients with rheumatoid arthritis.

Kauppi M, Pukkala E, Isomäki H.

J Rheumatol. 1996 Aug;23(8):1484-5. No abstract available.

PMID:
8856639
20.

Supplemental Content

Support Center